Is the Department of Health and Aged care, The TGA and ATAGI telling #Australian's the true picture of rise in Myocarditis (and it's seriousness) cases in #Australia post Covid-19 mRNA vaccines?
Like many (including myself), before mid-2021 (and certainly not in 2020) heard of Myocarditis (A rare heart disease). However, Mid 2021 this "rare" heart disease was not rare anymore.
In the #COVID19 Vaccine safety report published on 27th May 2021, TGA #Australia for the first time mentioned that they were investigating small number of Australian cases for Myocarditis and Pericarditis following #Pfizer vaccine.
In the #COVID19 Vaccine safety report published on 9th Dec 2021, the TGA reported that there were 2 fatal cases of suspected myocarditis following Comirnaty (Pfizer).
#Myocarditis cases were not consistent with being caused by vaccination.
In December 2021, the Health Department #Australia quietly updated the MBS Online website on Friday to announce the new temporary item being added to the Medicare Benefits Schedule from January 1, 2022 until June 30, 2022 as reported by .@franks_chung
Many were curious (and rightly so) and surprised to see the introduction of new MBS item (government-subsidized) for a Covid-19 mRNA vaccine adverse event which we all have been told is rare and mild.
Application 1713 submitted to Medical Services Advisory Committee (Dept. of Health and Aged care) by Cardiac Society of Australia and New Zealand (CSANZ) late 2021 provides an insight.
The applicant's (CSANZ) description of the proposed medical service:-
- Is a non-invasive imaging technique.
- Contrast agent utilizes gadolinium-based agents.
- Cardiac MRI is recognized as the gold standard for the non-invasive diagnosis of myocarditis.
Kindly read the medical condition described by the applicant (CSANZ) - Were we provided ALL the necessary information for us to make an INFORMED CONSENT?
"Patients with myocarditis usually present with one of two clinical syndromes. For both presentations the prodrome is relatively short (days to weeks), with a clinical history of viral infection (including Covid-19) often occurring within that time period. "
This is very concerning regarding the diagnostic pathway (before Cardiac MRI was introduced) which was in place for the entirety of 2021 for #Australia
#Australia didn't have government subsidized Cardiac MRI in place to diagnosis #Myocarditis post COVID-19 mRNA vaccine and ATAGI has been using definition(s) which are based on a Cardiac MRI we didn't have in place in 2021 - Unbelievable!!
A search of Service Australia Medicare statistics database show MBS item 63399 was requested 1612 times by medical providers across Australia during the period of 1 Jan 2022 - 31 Dec 2022 - WOAAHH!!
In Late 2022 (Nov 9), department of health #Australia's updated Myocarditis/Pericarditis guideline mentions late gadolinium enhancement (LGE) following cardiac MRI studies of patients & highlights that longer term follow-up studies are still in progress.
Item 663399 is no longer available under the Medicare Benefits Schedule (government subsidized) in #Australia which is very concerning given Cardiac MRI is recognized by most international cardiac societies as the gold standard for the non- invasive diagnosis of #myocarditis.
To 5th Feb, 2023, I'd like to highlight that there has been 12,599 cases of chest pain reported to the TGA DAEN following COVID-19 mRNA vaccines
I wonder what is keeping the Emergency department(s), our hospitals and and/or Ambulance services busy across #Australia ?
Australian Technical Advisory Group on Immunisation (ATAGI) announced on 8th Feb 2023 of #Pfizer Bivalent vaccine for use as a booster COVID-19 vaccine in people aged 12 years and older in #Australia
No immunogencity data available for 12 - 18 yrs of age group yet this #Pfizer bivalent #COVID19 vaccine is "provisionally" approved in #Australia for use as a booster COVID-19 vaccine in people aged 12 years and older.